RLAY Projected Dividend Yield
Relay Therapeutics Inc ( NASDAQ : RLAY )Relay Therapeutics Inc. is a clinical-stage precision medicine company. Co. is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Co.'s Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Co.'s lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3K?), inhibitor. 21 YEAR PERFORMANCE RESULTS |
RLAY Dividend History Detail RLAY Dividend News RLAY Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |